A61K 47/6881
Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies
Official title: {Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other}
A61K47/6881 (Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies) appears on 60 US grants and 86 published applications in this corpus.
Search patents in A61K- Granted patents
- 60
- Published applications
- 86
- Assignees
- 54
- Inventors
- 207
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 5 | 0 |
| 1998 | 3 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 3 | 2 |
| 2003 | 0 | 3 |
| 2004 | 1 | 2 |
| 2005 | 0 | 1 |
| 2006 | 1 | 2 |
| 2007 | 2 | 2 |
| 2008 | 0 | 1 |
| 2009 | 4 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 3 |
| 2012 | 1 | 1 |
| 2013 | 0 | 6 |
| 2014 | 0 | 1 |
| 2015 | 1 | 2 |
| 2016 | 1 | 4 |
| 2017 | 0 | 6 |
| 2018 | 1 | 5 |
| 2019 | 2 | 8 |
| 2020 | 3 | 8 |
| 2021 | 4 | 6 |
| 2022 | 2 | 3 |
| 2023 | 2 | 3 |
| 2024 | 3 | 5 |
| 2025 | 5 | 6 |
| 2026 | 2 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Dimeric antibodies5 May 2026US 12,616,756 B2Medicovestor, Inc.
- Multifunctional immunotherapeutic monoclonal antibody complexes and conjugates7 Apr 2026US 12,594,341 B2
- Anti-CD3 antibodies and methods of use11 Nov 2025US 12,466,896 B2Genentech, Inc.
- Long acting multi-specific molecules and related methods30 Sep 2025US 12,427,203 B2Shenzhen Enduring Biotech, Ltd.
- Homodimeric antibodies for use in treating cancers and methods of use22 Jul 2025US 12,364,777 B2Medicovestor, Inc.
- Lysosomal targeting bifunctional molecules for degradation of autoantibodies6 Aug 2026US 2026/0224719 A1Lycia Therapeutics, Inc.
- Multifunctional immunotherapeutic monoclonal antibody complexes and conjugates16 Jul 2026US 2026/0199506 A1
- Anti-cd3 antibodies and methods of use25 Jun 2026US 2026/0176375 A1Genentech, Inc.
- Antl-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof7 May 2026US 2026/0124314 A1Salubris Biotherapeutics, Inc.
- Bivalent, bispecific binding proteins for prevention or treatment of hiv infection9 Oct 2025US 2025/0312475 A1Sanofi
Most cited
By later US patents
- Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates493US 5,714,586 AAmerican Cyanamid Company · 1998
- Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates419US 5,712,374 AAmerican Cyanamid Company · 1998
- Anthracycline conjugates having a novel linker and methods for their production315US 5,122,368 ABristol-Myers Squibb Company · 1992
- Thioether conjugates293US 5,622,929 ABristol-Myers Squibb Company · 1997
- Antitumor protein hybrid and process for the preparation thereof135US 4,379,145 AHidematsu Hirai · 1983